|
Home
|
E-Submission
|
Sitemap
|
Contact Us
|
About KJIM
Aims and Scope
Editorial Board
Subscriptions
Open Access
Contact us
E-Submission
Instructions for Authors
Checklist
Instructions for Reviewers
Article-processing Charge
Ahead of Print
Current Issue
Archive
Most Read Articles
Most Cited Articles
KJIM Search
Author Index
Gastroenterology
Cardiology
Pulmonology
Endocrinology-metabolism
Nephrology
Hemato-oncology
Infectious diseases
Allergy
Rheumatology
Korean J Intern Med Search
> Browse Articles > Korean J Intern Med Search
Hemato-oncology
Clinical factors affecting progression-free survival with crizotinib in
ALK
-positive non-small cell lung cancer
Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med.
2019;34(5):1116-1124. Published online June 29, 2018
DOI:
https://doi.org/10.3904/kjim.2018.011
Cited By 1
Background/Aims: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (
ALK
)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factor..
Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance
Koung Jin Suh, Ki Hwan Kim, Ryul Kim, Ja Min Byun, Miso Kim, Jin Hyun Park, Bhumsuk Keam, Tae Min Kim, Jin-Soo Kim, In Sil Choi, Dae Seog Heo
Korean J Intern Med.
2019;34(4):894-901. Published online February 23, 2018
DOI:
https://doi.org/10.3904/kjim.2017.174
Cited By 1
Background/Aims: The role of [18F]-f luorodeoxyglucose positron emission tomography-computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) in first remission is unclear. Methods: Medical costs within the first 3 years of treatment completion and clinical outcomes of 118..
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo
Korean J Intern Med.
2019;34(4):885-893. Published online November 20, 2017
DOI:
https://doi.org/10.3904/kjim.2017.036
Cited By 3
Background/Aims: This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy. Methods..
Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
Junghoon Shin, Youngil Koh, Jeonghwan Youk, Miso Kim, Byung Soo Kim, Chul Won Choi, Hwa Jung Sung, Yong Park, Sung-Soo Yoon, Inho Kim
Korean J Intern Med.
2017;32(4):722-730. Published online June 26, 2017
DOI:
https://doi.org/10.3904/kjim.2016.256
Cited By 1
Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 ..
1
> Browse Articles > Korean J Intern Med Search
